Drug Profile
EC 1169
Alternative Names: DUPA-TubH III; EC 1719; EC-1069; EC1169; PSMA-TubulysinLatest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Endocyte
- Class Antineoplastics; Biological toxins; Drug conjugates; Peptides; Small molecules
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for phase-I development in Prostate-cancer(Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV, Injection)
- 21 Dec 2018 Endocyte has been acquired by Novartis
- 29 Nov 2018 Endocyte completes a phase I trial for Prostate cancer (late-stage disease, recurrent, Second-line therapy or greater)in USA (IV) (NCT02202447)